WO2004050886A1 - Ebウイルスベクターのためのパッケージング細胞システム - Google Patents
Ebウイルスベクターのためのパッケージング細胞システム Download PDFInfo
- Publication number
- WO2004050886A1 WO2004050886A1 PCT/JP2003/015419 JP0315419W WO2004050886A1 WO 2004050886 A1 WO2004050886 A1 WO 2004050886A1 JP 0315419 W JP0315419 W JP 0315419W WO 2004050886 A1 WO2004050886 A1 WO 2004050886A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- packaging
- cells
- producing
- genome
- Prior art date
Links
- 0 C*C(CC(*)C*)C*1C(*)C[C@](C)C1 Chemical compound C*C(CC(*)C*)C*1C(*)C[C@](C)C1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16241—Use of virus, viral particle or viral elements as a vector
- C12N2710/16243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to a method for producing an EB virus vector and a packaging cell system for use in the method.
- Epstein-Barr virus (hereinafter referred to as “EB virus”) is a kind of herpes virus and has the ability to infect human B lymphocytes and promote their proliferation.
- EB virus vectors are 1) more stable in cells for long periods of time compared to other virus-based vectors currently in use; 2) can incorporate large foreign genes of 10 Okb or more; 3) Genes can be transfected into B lymphocytes in the stationary phase, especially primary B lymphocytes in primary culture; 4) Genes can be transfected into B lymphocytes, which are antigen-presenting cells; 5) Genes have been transfected B lymphocytes can be expanded in vitro; 6)
- the use of a system for producing recombinant virus in E. coli makes vector preparation much easier, and has many advantages. I have.
- Akata cells As EB virus-producing cell lines, Akata cells, B95-8 cells, P3HR-1 cells and the like are known. Among them, Akata cells have approximately 20 copies of the circular EB virus genome in the nucleus, and can induce infectious EB virus production by adding an anti-human immunoglobulin antibody to a liquid medium. It is a cell line suitable for production (Tak ad aK, Int J Cancer 33, 27-32 (1984); Tak ad aK and Ono Y, J Virol 63, 445-449 (1989)).
- EB virus-negative Ak ata cells Clones from which the EB virus genome has been lost (hereinafter referred to as "EB virus-negative Ak ata cells”) obtained by long-term passage of Aka ta cells are re-infected with EB virus.
- the virus-producing ability by the treatment with the anti-human immunoglobulin antibody can be shown again (Japanese Patent Laid-Open No. 7-115966).
- Ak ata cells having only the modified EB virus genome can be produced.
- These cells have the ability to produce large amounts of recombinant EB virus by treatment with an anti-human immunoglobulin antibody (Japanese Patent Application Laid-Open No. 8-009971).
- the EB virus vector production is induced by exogenously introducing and expressing the EB virus early gene BZLF1 and the amplicon plasmid simultaneously into these 293 cells.
- this system is not suitable for mass production of EB virus vector because the method for producing EB virus vector is complicated and the titer of the produced EB virus vector is very low.
- a system for efficiently introducing a foreign gene into cells using the EB virus coat (Delecluse HJ, HammerscshmidtW, JClin Pathol: Mo 1 Pathol 2000) 53: 270-279, etc.) and a method of packaging a gene vector DNA containing no helper virus (JP-A-11-221073).
- An object of the present invention is to provide a system capable of efficiently and efficiently producing an EB virus vector having no virus replication ability. Disclosure of the invention
- the method of the present invention comprises:
- the EB virus packaging signal is deleted by homologous recombination by introducing the homologous recombination gene fragment from which the packaging signal has been deleted into EB virus-positive Ak ata cells, and
- the method of the present invention comprises:
- An EB virus genome lacking a packaging signal is prepared using Escherichia coli, the EB virus genome is introduced into EB virus-positive Akata cells, and the EB virus genome lacking a packaging signal is retained. Cloning packaging cells that do not carry the wild-type Epstein-Barr virus genome with the signaling
- the method of the present invention comprises:
- the present invention relates to an amplicon plasmid-introduced Ak ata packaging for producing an EB virus vector having no viral replication ability.
- a method for producing a cell includes a step of introducing an amplicon plasmid having a packaging signal but not having a virus replication ability into a packaging cell obtained by any of the methods described above.
- the present invention provides an EB virus enveloped in a virus coat by inducing lytic infection of Akta packaging cells into which the amplicon plasmid produced by the above-described method of the present invention has been introduced.
- a method for producing an EB virus vector having no virus replication ability, comprising releasing a vector comprising releasing a vector.
- the present invention provides a method for releasing an EB virus vector wrapped in a viral envelope by inducing lytic infection of an amplicon plasmid-introduced Akata packaging cell produced by the above-described method of the present invention. And infecting B lymphocytes with the obtained EB virus vector.
- EB virus vectors having no virus replication ability can be easily and efficiently produced by inducing lytic infection of amplicon plasmid-introduced packaging cells prepared by introducing amplicon plasmids into packaging cells. Can be. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 shows a method for producing a packaging cell of the present invention.
- FIG. 2 shows the production of the EB virus vector by the Akata packaging cell introduced with the amplicon plasmid.
- FIG. 3 shows the cloning of the packaging signal gene (TR) and the construction of a targeting plasmid to disrupt the packaging signal.
- FIG. 4 shows the positions of primers used for confirmation of homologous gene recombination.
- FIG. 5 shows the positions of primers used for gene amplification to confirm the loss of wild-type EB virus.
- FIG. 6 shows an example of the structure of a TR deletion present in an amplicon plasmid-introduced packaging cell.
- FIG. 7 shows EB virus vector production by amplicon plasmid-transfected packaging cells.
- FIG. 8 shows the production of a virus that cannot replicate the virus genome and the production of an EB virus vector that cannot replicate the virus genome using packaging cells into which the virus genome has been introduced.
- FIG. 9 shows the construction of a plasmid for overnight get to disrupt and delete the BALF2 gene and the probe used for detection of the homologous recombination virus.
- FIG. 10 shows the positions of primers used for gene amplification to confirm that the BALF2 gene deleted virus was produced by homologous recombination.
- the present invention provides a method for producing a packaging cell used for producing a system for producing an EB virus vector having no virus replication ability.
- a “packaging cell” is a cell that lacks a packaging signal but has an EB virus genomic that is capable of expressing the viral proteins necessary to make virus particles.
- a packaging signal is a cis-acting sequence necessary for a gene to be packaged in an EB virus particle, and is also called TR (Terminal 1 Repeat).
- TR Terminal 1 Repeat
- “deleted” means that all of the packaging signal has been deleted, and that a part of the packaging signal has been deleted or mutated. This includes both cases of loss of function.
- EB virus vector is meant a virus particle that has the ability to infect human B lymphocytes over the EB virus envelope.
- the EB virus vector may contain a foreign gene.
- EB virus vector that does not have the ability to replicate virus is a virus that infects host cells and can replicate the genome in those cells, but when the cells are induced to undergo lytic infection, the virus coats. A vector that is not released as a virus particle in a
- the Akata cells used in the present invention are known human lymphocytes and have approximately 20 cyclic EB wills in the nucleus.
- a virus can be produced (Japanese Patent Application Laid-Open No. Hei 8-009971).
- Akata cells can isolate clones in which the EB virus genome has been eliminated by long-term passage (Japanese Patent Laid-Open Publication No. 7-115966), the same method holds only the recombinant EB virus genome, and the wild-type EB virus genome Dropped cell clones can be isolated.
- Ak ata cells can produce large amounts of EB virus by treatment with an anti-pytoimmunoglobulin antibody (Takada K, Int J Cancer 33 ,: 27-32 (1984); Takada K and ⁇ no Y, JVirol 63, 445-449 (1989)).
- FIG. 1 A schematic of a first embodiment of the method of the invention is shown in FIG.
- the packaging signal of the EB virus is deleted by homologous recombination in the EB virus positive Ak ata cells.
- This step is performed by introducing a gene fragment for homologous recombination having a region flanking the packaging signal and lacking the packaging signal into EB virus-positive Akata cells.
- the gene fragment for homologous recombination preferably has a length of 3 Okb or less, more preferably 2 Okb or less.
- Such gene fragments can be generated in E. coli systems based on known EB virus gene sequences.
- the gene can be introduced by an electroporation method, a calcium phosphate method, a lipofection method, a gene gun method, or the like.
- an Akata cell clone having both the Akata EB virus genomic genome and the wild-type EB virus genome that lacks the packaging signal is isolated.
- the neomycin resistance gene is used in FIG. 1 for selection of recombinant viruses, any selection technique that works in Akata cells may be used.
- the isolated cell clone is treated with hydroxyperea and re-divided into cell clones, whereby the wild-type virus is shed and the packaging cells that retain only the virus that lacks the packaging signal are isolated. Can be. Cloning can also be performed by subculturing and limiting dilution without using hydroxyurea.
- the step of deleting the packaging signal of the EB virus by homologous recombination comprises: introducing the EB virus DNA into an artificial E. coli chromosome, introducing the DNA into E. coli; Packaged by genetic modification This is performed by preparing an EB virus genome lacking the signaling signal and introducing it into EB virus-positive Akata cells. This is because EB virus-positive Ak ata cells have higher transduction efficiency of exogenous genes than EB virus-negative Akata cells and can grow stably.
- a gene fragment for homologous recombination was prepared by inserting an E. coli artificial chromosome (BAC) vector fragment derived from pBe1oBAC11 (Genome Systems) into a gene fragment derived from the EB virus genome. This is introduced into Akata cells having a wild-type circular EB virus genome, and clones that have undergone homologous recombination are selected.
- Escherichia coli is transformed with the genomic DNA prepared from this clone to obtain a plasmid containing BAC and EB virus genome derived from Akata cells.
- any site of the EB virus genome on this plasmid can be deleted or mutated.
- the BAC-EB virus DNA having the packaging signal thus deleted, which has been deleted, can be introduced into Akat cells to cause homologous recombination in the Akat cells.
- the step of deleting the packaging signal of the EB virus by homologous recombination comprises introducing the EB virus DNA into an artificial E. coli chromosome, introducing the EB virus DNA into E. coli, This is performed by creating an EB virus genome from which the packaging signal has been deleted by genetic recombination and introducing it into Akata cells that are EB virus negative and express EBNA1.
- Aka ta cells expressing EB NA1 are transfected with EB virus-negative A kata cells using linear DNA linked to the EB NA1 gene and an appropriate antibiotic resistance gene, and then selected with this antibiotic. By doing so, it is possible to close.
- the EBNA1 protein is an essential protein for the EB virus to be replicated and maintained as an episome in the cell nucleus, and it is considered that EBNA1-expressing Akata cells have a high efficiency of episomal formation.
- the present invention also provides a packaging cell produced by the above method.
- An amplicon plasmid introduced by introducing a foreign gene (amplicon) containing a packaging signal into the packaging cell of the present invention.
- a foreign gene amplicon
- the packaging cell of the present invention has a helper function for producing an EB virus vector containing a foreign gene and having no virus replication ability.
- the present invention provides a method for producing an amplicon plasmid-introduced Akata cell for producing an EB virus vector having no virus replication ability.
- the outline of this method is shown in FIG.
- the amplicon plasmid can be introduced by an electroporation method, a calcium phosphate method, a lipofection method, a gene gun method, or the like.
- Amplicon plasmid refers to a plasmid (circular DNA) containing a virus-derived gene but lacking virus-producing ability.
- An amplicon plasmid is a circular DNA that contains a packaging signal and a viral origin of replication and lacks one or more genes encoding proteins essential for viral replication.
- the amplicon plasmid has a gene for selection.
- the amplicon plasmid has a packaging signal, an origin of replication in the EB virus latent infection phase, oriP, an origin of replication in the EB virus lytic infection induction phase, oriLyt, and EBNA1. Further, when the EB virus vector is used for introducing a foreign gene, the amplicon plasmid further has a desired foreign gene to be introduced.
- the amplicon plasmid has a puromycin resistance gene as its primary function, and Amplicon plasmid-introduced Akata packaging cells in which amplicon has been introduced by puromycin are selected.
- any selection technique that works with this cell may be used.
- a selection marker different from the selection marker used for preparing the packaging cells is used.
- the introduction of the amplicon plasmid into the packaging cells may also use a method by infection with a virus that cannot replicate the viral genome. The outline of this method is shown in FIG. In EB virus-positive A kata cells, a gene important for EB virus genome replication is deleted by homologous recombination. In FIG.
- the hygromycin resistance gene is used for selection of the homologous recombinant virus.
- Treatment of the isolated A kata cell clone with both the homologous recombinant virus and the wild-type virus with an anti-human immunoglobulin antibody allows the deleted EB virus gene product to be supplied from the wild-type virus and homologated. Both recombinant and wild-type viruses are produced.
- the produced virus solution is used to infect packaging cells, and selected using the selection marker (neomycin) used to generate the packaging cells and the selection marker used to generate the virus that cannot replicate the viral genome (idalomycin).
- TR (1) the amplicon plasmid containing only the EB virus gene lacking the packaging signal and the EB virus gene lacking the gene important for replication of the virus genome was introduced. Isolate kata packaging cells. The A-kata packaging cells containing the EB virus gene lacking the gene important for viral genome replication as an amplicon thus obtained are treated with an anti-human immunoglobulin antibody to obtain an EB virus. Only the amplicon plasmid with the virus coat is released as an EB virus vector.
- the present invention also provides an Akata packaging cell having the introduced amplicon plasmid produced by the method described above.
- the A kata packaging cell having the amplicon plasmid of the present invention has the ability to produce an amplicon plasmid DNA coated with an EB virus coat as an EB virus vector by treatment with an anti-human immunoglobulin antibody. .
- the genome of EB virus is extended and replicated in the form of a rolling circle, but is not excised if the packaging signal is deleted, and therefore is not incorporated into the virus particle.
- the gene of the 7 amplicon plasmid also elongates in a rolling cycle format, and the amplicon forms a concatemer, which is cleaved at the packaging signal, and has a size of about 170 kb, the size of the EB virus genome.
- Packaged in size See Figure 7). That is, only the amplicon plasmid in which the EB virus coat is covered is released as the EB virus vector.
- the A kata packaging cell having the amplicon plasmid produced by the method of the present invention can be used to convert an EB virus vector having no virus replication ability at a maximum efficiency of at least 1,000 times that of the conventional method. Produces and does not produce wild-type EB virus.
- the present invention relates to an EB virus vector wrapped in a virus coat by inducing lytic infection of an amplicon plasmid-introduced Akata packaging cell produced by the above-described method of the present invention. And a method for producing an EB virus vector having no virus replication ability, which comprises releasing EB virus. Induction of lysis and infection of the Akata packaging cells into which the amplicon plasmid has been introduced can be easily performed by treatment with an anti-imnoglobulin antibody.
- the present invention also provides an EB virus vector produced according to the above method.
- This EB virus vector contains the amplicon plasmid in the EB virus particle and has the ability to infect and immortalize B lymphocytes, but does not have the ability to replicate itself as a virus particle. Therefore, a human antibody can be easily produced by infecting a B lymphocyte producing the desired antibody with the EB virus vector of the present invention, immortalizing it, and growing it in an in vitro mouth. That is, the present invention also provides a method for producing immortalized B lymphocytes using the EB virus vector of the present invention, and an immortalized B lymphocyte produced by the method of the present invention.
- Example 1
- the packaging signal of the Akata strain EB virus was disrupted based on the method of FIG.
- the Bam-Nhet region of the 8 kb Akat strain EB virus was cloned into pUC119 to produce pUC119Net (Fig. 3a).
- TR packaging signal
- a neomycin resistance gene neo and red pigment gene (DsRed)
- TR destroyed the gene disruption.
- the plasmid pUCNhnetneRed was prepared (Fig. 3b), and this plasmid DNA was transfected into EB virus-positive Akata cells by electroporation.
- ANC F1 and ANC R2 are primers designed outside the 5 'end and 3' end of the recombination site, respectively, and ANC R1 and ANC F 2 are primers designed inside neo r .
- Figure 4 shows the approximate position and direction of each primer. If homologous recombination has occurred, a 5.3 kb DNA fragment is amplified by a primer pair of ANCF 1 and ANC R1, and a 10.3 kb DNA fragment is amplified by a primer pair of ANC F2 and ANC R2. DNA fragments are amplified. None is amplified if no homologous recombination has taken place. 12 clones in this way Confirmed that the EBV carried the homologous recombination EB virus.
- TR (—) After culturing 119 cells, a clone retaining the EB virus genome, in a selection medium (50% EB virus-negative A kata cell culture supernatant, 0.35 mg Zml G418, 50 hydroxyrea) for 10 days Cultivation was further continued for 10 days except for hydroxyperia. Culture is performed by diluting the cells into a 96-well plate so that 0.5 cells are contained in each well, and the amplified clones are subjected to gene amplification using primer pairs designed outside the TR, and the wild-type band (2.
- a selection medium 50% EB virus-negative A kata cell culture supernatant, 0.35 mg Zml G418, 50 hydroxyrea
- an amplicon plasmid was prepared.
- An amplicon plasmid must have a structure with a packaging signal (TR).
- TR packaging signal
- having the replication origin ori P at the EB virus latent infection stage and having the EBNA1 gene that activates ori P in trans is important for the maintenance of the plasmid in the transfected cells.
- Having an origin of replication ⁇ ri Lyt is necessary for the production of an EB virus vector from amplicon plasmid-introduced packaging cells by stimulation with anti-human immunoglobulin.
- Figure 6b shows the prepared amplicon plasmid.
- the EB virus gene contains only EBNA-1, oriP, TR, and oriLit, and is used for selection of green fluorescent protein (GFP) gene and amplicon plasmid to be maintained in cells for overnight repo This is a 21 kb amplicon plasmid (pPs i) into which the puromycin resistance gene has been inserted.
- GFP green fluorescent protein
- the helper virus genome is extended and replicated in a mouth-to-ring cycle format, but is not excised because it lacks TR. Therefore, it is not incorporated into virus particles.
- the gene of the amplicon plasmid Elongate in a ring cycle format, the amplicons form concatemers, are cut at the TR, and are packaged at a size of approximately 17 Okb, the size of the EB virus genome ( Figure 7). That is, EB virus having the gene of the amplicon plasmid is released.
- Example 3 the gene of the amplicon plasmid —Elongate in a ring cycle format, the amplicons form concatemers, are cut at the TR, and are packaged at a size of approximately 17 Okb, the size of the EB virus genome ( Figure 7). That is, EB virus having the gene of the amplicon plasmid is released.
- the amplicon plasmid pPSi thus prepared was transfected into a packaging cell by electroporation using 0.3 S gZml puromycin, 50% EB virus-negative Akata cell culture supernatant, and 0.35 mgZml G418. Selection culture was performed. The resulting 72 puromycin resistant clones were all GFP positive. One of the clones was treated with an anti-human immunoglobulin antibody, and it was confirmed that the capsid antigen (VCA), which is a constituent protein of the EB virus, was expressed, and that no wild-type virus was present in the supernatant. Furthermore, when the recombinant EB virus in the supernatant was infected to EB virus-negative Daudi cells, it was confirmed that nearly 20% of the cells were infected with the recombinant EB virus and expressed GFP.
- VCA capsid antigen
- the BALF2 gene encoding the EB virus single-stranded DNA binding protein of the AK virus strain EB virus was replaced with a hygromycin resistance gene to destroy and delete it, based on the method of FIG.
- clone the 11,429 base pair EcoR I—Sa1I fragment of the EcoDet and Eco—J regions of the pUCl l ⁇ ; iAkata strain EB virus By removing the C1aI-EcoRV region and inserting and replacing a 1,853-base pair hygromycin resistance gene, a plasmid pUCl19EcoD—JHyg for gene disruption in which the BALF2 gene was disrupted was transformed. It was fabricated (Fig. 9a). A 7,807 base pair SacI-Bg1II fragment of this plasmid DNA was transfected into EB virus-positive AkAta cells by electroporation.
- F 1 and R 2 are primers designed outside the 5 ′ end and 3 ′ end of the recombination site, respectively, and Hyg F and Hyg R are primers designed inside the hygromycin resistance gene, respectively.
- Figure 10 shows the approximate position and direction of each primer. If homologous recombination has occurred, the F1 and HygR primer pair will amplify a 4,112 base pair DNA fragment, and the HygF and R2 primer pair will generate a 4,534 base pair DNA fragment. Amplified. If no homologous recombination has occurred, nothing is amplified. By this method, it was confirmed that two clones contained homologous recombinant EB virus.
- the clone carrying the homologous recombination EB virus was treated with an anti-human immunoglobulin antibody to produce a virus in which both the recombinant type and the wild type were mixed.
- the produced virus solution was used to infect the packaging cells prepared in Example 1, and the cells were cloned in the presence of neomycin and hygromycin to obtain the EB virus genome lacking the BALF2 gene and TR as a helper.
- Ak ata packaging cells containing only the EB virus genome and no wild-type virus genome were isolated.
- the Ak ata packaging cells were treated with an anti-human immunoglobulin antibody, and an EB virus vector consisting of only the BALF 2 gene-deficient EB virus was recovered.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003302709A AU2003302709A1 (en) | 2002-12-02 | 2003-12-02 | Packaging cell system for eb virus vector |
JP2004556890A JPWO2004050886A1 (ja) | 2002-12-02 | 2003-12-02 | Ebウイルスベクターのためのパッケージング細胞システム |
EP03812371A EP1580276A1 (en) | 2002-12-02 | 2003-12-02 | Packaging cell system for eb virus vector |
US10/537,263 US20060194203A1 (en) | 2002-12-02 | 2003-12-02 | Packing cell system for eb virus vector |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002349467 | 2002-12-02 | ||
JP2002-349467 | 2002-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004050886A1 true WO2004050886A1 (ja) | 2004-06-17 |
Family
ID=32463041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015419 WO2004050886A1 (ja) | 2002-12-02 | 2003-12-02 | Ebウイルスベクターのためのパッケージング細胞システム |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060194203A1 (ja) |
EP (1) | EP1580276A1 (ja) |
JP (1) | JPWO2004050886A1 (ja) |
AU (1) | AU2003302709A1 (ja) |
WO (1) | WO2004050886A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104604799A (zh) * | 2015-02-05 | 2015-05-13 | 南华大学 | 一种鉴定eb病毒对淋巴瘤的诱发性的方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2065462A1 (en) * | 2007-11-27 | 2009-06-03 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023603A1 (fr) * | 1994-07-05 | 1997-07-03 | Yamamoto, Naoki | Procede d'isolement et de developpement de virus epstein-barr (eb) recombines |
EP0915165A1 (de) * | 1997-11-05 | 1999-05-12 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verfahren zur helfervirusfreien Verpackung einer Genvektor-DNA |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE259421T1 (de) * | 1997-11-05 | 2004-02-15 | Gsf Forschungszentrum Umwelt | Dna-virus-vektoren und verfahren zu ihrer herstellung |
-
2003
- 2003-12-02 WO PCT/JP2003/015419 patent/WO2004050886A1/ja not_active Application Discontinuation
- 2003-12-02 EP EP03812371A patent/EP1580276A1/en not_active Withdrawn
- 2003-12-02 JP JP2004556890A patent/JPWO2004050886A1/ja active Pending
- 2003-12-02 US US10/537,263 patent/US20060194203A1/en not_active Abandoned
- 2003-12-02 AU AU2003302709A patent/AU2003302709A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023603A1 (fr) * | 1994-07-05 | 1997-07-03 | Yamamoto, Naoki | Procede d'isolement et de developpement de virus epstein-barr (eb) recombines |
EP0915165A1 (de) * | 1997-11-05 | 1999-05-12 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verfahren zur helfervirusfreien Verpackung einer Genvektor-DNA |
Non-Patent Citations (2)
Title |
---|
DELECLUSE, H.J. ET AL.: "A first-generation packaging cell line for Epstein-Barr virus-derived vectors", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 9, 1999, pages 5188 - 5193, XP002966063 * |
SHIMIZU, N. ET AL.: "Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells", J. VIROL., vol. 70, no. 10, 1996, pages 7260 - 7263, XP002977617 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104604799A (zh) * | 2015-02-05 | 2015-05-13 | 南华大学 | 一种鉴定eb病毒对淋巴瘤的诱发性的方法 |
CN104604799B (zh) * | 2015-02-05 | 2017-11-21 | 南华大学 | 一种鉴定eb病毒对淋巴瘤的诱发性的方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1580276A1 (en) | 2005-09-28 |
US20060194203A1 (en) | 2006-08-31 |
AU2003302709A1 (en) | 2004-06-23 |
JPWO2004050886A1 (ja) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chang et al. | Cloning of the full-length rhesus cytomegalovirus genome as an infectious and self-excisable bacterial artificial chromosome for analysis of viral pathogenesis | |
JP3895366B2 (ja) | ウィルス ワクチン | |
CN1989250B (zh) | Tc-83衍生的甲病毒属载体、颗粒和方法 | |
AU2006212393B2 (en) | Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products | |
Redwood et al. | Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception | |
JP4024830B2 (ja) | Hhv−7由来の組換ウイルスベクター、その製造方法、それを用いた宿主細胞の形質転換方法、それにより形質転換された宿主細胞およびそれを用いた遺伝子治療方法 | |
Delecluse et al. | The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy | |
Strive et al. | Proteolytic processing of human cytomegalovirus glycoprotein B is dispensable for viral growth in culture | |
WO1997035996A1 (en) | Packaging cell line based on human 293 cells | |
Borst et al. | Construction of a cytomegalovirus-based amplicon: a vector with a unique transfer capacity | |
EP1664312B1 (en) | Rodent expression systems utilising polyoma virus and epstein barr virus sequences | |
WO2004050886A1 (ja) | Ebウイルスベクターのためのパッケージング細胞システム | |
AU747831B2 (en) | DNA virus vectors and methods for their preparation | |
AU1138897A (en) | Episomal vector and uses thereof | |
AU747763B2 (en) | Method for helper virus-free packaging of a gene vector DNA | |
JP2005536226A (ja) | ベクターとしての非ヒトヘルペスウイルス | |
EP1457565A1 (en) | Double-stranded cyclic dna capable of proliferating as artificial e. coli chromosome | |
WO2009053988A1 (en) | Production of bac vectors carrying viral genomes | |
CA2154854C (en) | Immortalized lymphocytes for production of viral-free proteins | |
JP6761946B2 (ja) | 巨大環状ウイルスゲノムdnaの単離方法 | |
CN117683737A (zh) | 建立基于水疱性口炎病毒载体的复制型重组病毒用于研究SADS-CoV入侵和疫苗开发 | |
JPS6398381A (ja) | Lpvを基にした組織特異性ウイルスベクターおよびその使用 | |
Delecluse et al. | Bernhard Neuhierl, Regina Feederle, Dinesh Adhikary | |
Full | Cytomegalovirus specific activation of cytotoxic T lymphocytes by chimeric immunoreceptors | |
Artificial et al. | Cloning of the Full-Length Rhesus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004556890 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006194203 Country of ref document: US Ref document number: 10537263 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003302709 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003812371 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003812371 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003812371 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10537263 Country of ref document: US |